A Phase 3 Trial of
            <scp>l</scp>
            -Glutamine in Sickle Cell Disease

Niihara, Yutaka; T. Miller, Scott; Kanter, Julie; Lanzkron, Sophie; R. Smith, Wally; L. Hsu, Lewis; R. Gordeuk, Victor; Viswanathan, Kusum; Sarnaik, Sharada; Osunkwo, Ifeyinwa; Guillaume, Edouard; Sadanandan, Swayam; Sieger, Lance; L. Lasky, Joseph; H. Panosyan, Eduard; A. Blake, Osbourne; N. New, Tamara; Bellevue, Rita; T. Tran, Lan; L. Razon, Rafael; W. Stark, Charles; D. Neumayr, Lynne; P. Vichinsky, Elliott

doi:10.1056/nejmoa1715971

Public

A Phase 3 Trial of l‐Glutamine in Sickle Cell Disease

Shared by NobleBlocks on Jul 18, 2018 • 12:00 AM UTC

Authors:

Y. Niihara

Scott T. Miller

J. Kanter

Abstract

BACKGROUND Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical‐grade l‐glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which p...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!